pbft02
pbft02: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Passage BIO, Inc. (PASG) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the ICM of Adults With FTD and Mutations in the GRN or C9ORF72 Genes
FDA Decisions
FDA_MeetingThe IDMC and FDA agreed that dosing of Patient 9 may proceed with additional safety monitoring in place prior to protocol amendment completion.(PASG)
Frequently asked questions
Who is developing pbft02?
pbft02 is being developed by Passage BIO, Inc..
How many clinical trials involve pbft02?
BioSniper tracks 1 clinical trial involving pbft02.
What is pbft02's latest FDA decision?
The most recent tracked FDA decision for pbft02 is FDA_Meeting for The IDMC and FDA agreed that dosing of Patient 9 may proceed with additional safety monitoring in place prior to protocol amendment completion..
Get deeper analysis on pbft02
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis